Sanofi (SNY)
- Previous Close
46.61 - Open
48.80 - Bid 49.29 x 1000
- Ask 56.69 x 100
- Day's Range
48.65 - 49.83 - 52 Week Range
42.63 - 56.26 - Volume
6,469,548 - Avg. Volume
1,929,487 - Market Cap (intraday)
125.125B - Beta (5Y Monthly) 0.45
- PE Ratio (TTM)
21.55 - EPS (TTM)
2.29 - Earnings Date --
- Forward Dividend & Yield 2.04 (4.37%)
- Ex-Dividend Date May 9, 2024
- 1y Target Est
59.12
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
www.sanofi.com86,088
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: SNY
Performance Overview: SNY
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SNY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SNY
Valuation Measures
Market Cap
117.16B
Enterprise Value
127.27B
Trailing P/E
20.35
Forward P/E
11.38
PEG Ratio (5yr expected)
0.86
Price/Sales (ttm)
2.37
Price/Book (mrq)
1.48
Enterprise Value/Revenue
2.74
Enterprise Value/EBITDA
10.10
Financial Highlights
Profitability and Income Statement
Profit Margin
11.73%
Return on Assets (ttm)
4.54%
Return on Equity (ttm)
7.27%
Revenue (ttm)
46.03B
Net Income Avi to Common (ttm)
5.4B
Diluted EPS (ttm)
2.29
Balance Sheet and Cash Flow
Total Cash (mrq)
8.71B
Total Debt/Equity (mrq)
24.78%
Levered Free Cash Flow (ttm)
8.19B
Research Analysis: SNY
Company Insights: SNY
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: SNY
Daily Spotlight: Global Stocks a Bargain Compared to U.S. Stocks
As global markets struggle in the environment of higher interest rates, renewed conflict in the Middle East, and the lingering battle between Russia and Ukraine, one thing has not changed: foreign stocks are cheaper than U.S. stocks. And with the large run-up in late 2023 and first quarter of 2024, U.S. stocks are even more expensive. Consider P/E ratios. The trailing P/E ratio on the S&P 500 is 26, above the global average of 14 and well above the 6-12 average P/Es for stocks in emerging markets. A review of yields tells a similar story. The current dividend yield for the S&P 500 is 1.3%, versus the global average of 2.8% and Asian, Australian, and Latin American yields of 2%-5%. The foreign region that does not completely fit the pattern is the Middle East. The average P/E on a Saudi Arabian stock is a high 18.1 and the yield is a low 2.3%. This can be attributed to high oil prices. Taking a step back, investors generally are willing to pay a higher price for North American securities because of the transparency of the U.S. financial system as well as the liquidity of U.S. markets. What is more, global returns can be volatile across individual countries, given currency, security, political, and geopolitical risks. Indeed, U.S. stocks (ETF SPY) have outperformed EAFE (ETF EFA) over the past year as well as over the past five years. Even so, we recommend that growth investors have approximately 5%-10% of their equity allocations in international stocks to take advantage of the value, and we have been adding global stocks to our Universe of Coverage.
Analyst Report: Sanofi SA
Based in Paris, Sanofi focuses on treatments for diabetes and cardiovascular conditions as well as on specialty care and general medicines and consumer healthcare products. The company derives most of its revenue from the U.S., Europe, and emerging markets. It employs more than 87,000 people.
RatingPrice TargetMarket Update: SNY, EOG
Markets moved higher on Wednesday morning on ISM data. Services PMI increased to 51.4% in March. Prices paid hit the lowest level since March 2020. The focus will now be on Fed Chair Powell, who will speak later today. Treasury yields are rising. The S&P 500 rose 0.4%, the Dow was up less than 0.1% and the Nasdaq gained 0.3%. Crude oil traded above $85 per barrel and gold was up $23 to $2305 per ounce.
Weekly Stock List
We see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.